References
Ohno S, Nakamura S, Hori S, et al. Efficacy, safety, and pharmacokinetics of multiple administration of infliximab in Behçet’s disease with refractory uveoretinitis. J Rheumatol 2004;31:1362–1368.
Farrell RJ, Alsahli M, Jeen Y-T, et al. Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn’s Disease: a randomized controlled trial. Gastroenterology 2003;124:917–924.
Takeuchi T, Miyasaka N, Inoue K, et al. Impact of trough serum level on radiographic and clinical response to infliximab plus methotrexate in patients with rheumatoid arthritis: results from the RISING study. Mod Rheumatol 2009;19:478–487.
Lipsky PE, van der Heijde DMF, St Claire EW, et al. Anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study group. Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med 2000;343:1594–1602.
Author information
Authors and Affiliations
Corresponding author
About this article
Cite this article
Ito, T., Sonoda, KH., Hijioka, K. et al. Acquired resistance to infliximab against uveitis due to Behçet’s disease after one year of administration. Jpn J Ophthalmol 54, 502–504 (2010). https://doi.org/10.1007/s10384-010-0859-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10384-010-0859-0